Shares of LivaNova PLC (NASDAQ:LIVN – Get Rating) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $101.50.
A number of equities research analysts have recently weighed in on LIVN shares. Wolfe Research started coverage on shares of LivaNova in a research note on Tuesday, April 5th. They issued an “outperform” rating and a $95.00 price target on the stock. UBS Group upgraded shares of LivaNova from a “neutral” rating to a “buy” rating and set a $96.00 price target on the stock in a research note on Thursday, February 24th. Needham & Company LLC reduced their price target on shares of LivaNova from $120.00 to $106.00 and set a “buy” rating on the stock in a research note on Thursday, February 24th. Piper Sandler reduced their price target on shares of LivaNova from $104.00 to $99.00 in a research note on Thursday, May 5th. Finally, StockNews.com initiated coverage on shares of LivaNova in a research report on Thursday, March 31st. They set a “hold” rating on the stock.
LIVN opened at $65.05 on Friday. LivaNova has a twelve month low of $58.18 and a twelve month high of $93.89. The company has a 50-day simple moving average of $77.39 and a 200 day simple moving average of $79.84. The company has a quick ratio of 2.26, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of -32.69 and a beta of 0.91.
In other LivaNova news, CEO Damien Mcdonald sold 2,784 shares of the firm’s stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $81.50, for a total transaction of $226,896.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $83.42, for a total transaction of $83,420.00. Following the transaction, the director now owns 24,630 shares of the company’s stock, valued at approximately $2,054,634.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,784 shares of company stock valued at $470,316. Company insiders own 0.37% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Column Capital Advisors LLC increased its stake in shares of LivaNova by 109.1% in the 1st quarter. Column Capital Advisors LLC now owns 345 shares of the company’s stock valued at $28,000 after acquiring an additional 180 shares in the last quarter. First Horizon Advisors Inc. increased its stake in shares of LivaNova by 892.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 387 shares of the company’s stock valued at $46,000 after acquiring an additional 348 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in LivaNova during the 3rd quarter valued at $88,000. US Bancorp DE increased its stake in LivaNova by 15.3% during the 3rd quarter. US Bancorp DE now owns 1,564 shares of the company’s stock valued at $123,000 after purchasing an additional 208 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in LivaNova during the 1st quarter valued at $155,000. Institutional investors own 97.34% of the company’s stock.
About LivaNova (Get Rating)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
- Get a free copy of the StockNews.com research report on LivaNova (LIVN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.